Adial Pharmaceuticals expands its IP with a U.S. patent for targeted AUD treatment using AD04, supporting its personalized medicine strategy.
EXCLUSIVE: Adial Pharmaceuticals’ Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype Combinations
